Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients

Fig. 2

Adverse events following ide-cel administration. A Frequency and grade of presentation, B Median time to onset and duration of hematologic toxicity. Dashed lines show the upper limit of the median duration range. Abbreviations: CRS: cytokine release syndrome; DIC: disseminated intravascular coagulation; ICANS: immune effector cell-associated neurotoxicity syndrome

Back to article page